Stock Ratings / Health Care / DARE / financials

BFRI (40) RKTO (44) ALLR (38) LPCN (37) ⌘ Pro Terminal →

Dare Bioscience Inc. (DARE) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.68 +0.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.68

Dare Bioscience Inc. (DARE) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $13.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.68 (-0.15%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DARE)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY DARE SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$0.77-5.2% Next Q

Q2 (-2Q)

Grade D$0.73-11% Next Q

Q3 (-1Q)

Grade D$0.65+4.6% Next Q

Current

Grade D$0.68-6.5% Hist 90D α

Trajectory: C- (52) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DARE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DARE currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.75) and Max Pain ($0.71) forces dealer call-delta covering toward $3.97.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DARE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DARE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How DARE Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $2.8M

FY24

Rev $9.8K

FY25

Rev $1.0M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$1.0M	71.3%	-80%	-$13.4M	-$10.3M	-45%
FY 2024	$9.8K	98%	-80%	-$4.0M	$4.9M	-45%
FY 2023	$2.8M	71.3%	-80%	-$30.2M	-$38.9M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DARE)

✓Walkthrough of DARE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DARE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -70.18%▲ RESISTANCE BREAKOUT

2026-10-30O $0.70H $0.70L $0.67C $0.68VOL 651.5K

RES: $0.56SUP: $0.62SMA50: $0.75SMA200: $1.58

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DARE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DARE Butterfly Map → + Track DARE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DARE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DARE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DARE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DARE)

Health Care Rank #523 of 1016 ⚔️ BFRI vs DARE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DARE vs. BFRI, RKTO, ALLR, LPCN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Dare Bioscience Inc. (DARE) ranks #523 by composite RQD confidence (44/100, grade D) and #867 by equity capitalization ($13.4M). Within this direct 5-issuer industry benchmark cohort, DARE leads on earnings valuation at N/A trailing P/E, while DARE leads on capital efficiency and profitability with -35.0% ROIC and 71.3% gross margin. DARE currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DARE ACTIVE Dare Bioscience Inc.	D	44/100	—	71.3%	-35.0%	+0.22%	$13.4M	Benchmark Subject
BFRI Biofrontera Inc.	D-	40/100	—	—	-35.0%	+5.09%	$13.8M	/bfri-vs-dare →
RKTO Rocket One Inc.	D	44/100	—	—	-35.0%	-4.96%	$12.8M	/rkto-vs-dare →
ALLR Allarity Therapeutics Inc.	D-	38/100	—	—	-35.0%	-6.32%	$14.2M	/allr-vs-dare →
LPCN Lipocine Inc.	D-	37/100	—	—	-35.0%	+0.66%	$12.5M	/lpcn-vs-dare →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001401914

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dare Bioscience Inc. (DARE) reported GAAP revenue of $1.0M (+10429.4% vs. FY2024 revenue of $9.8K , and -63.3% cumulative change since FY2023) , GAAP net income of -$13.4M, operating cash flow of -$9.9M, and free cash flow of -$10.3M (-309.6% YoY). On the balance sheet, DARE closed FY2025 with $32.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.0M	-$13.4M	-$9.9M	-$10.3M	$32.5M	—
FY2024 (FY)	2024-12-31	$9.8K	-$4.0M	$5.5M	$4.9M	$22.1M	—
FY2023 (FY)	2023-12-31	$2.8M	-$30.2M	-$38.9M	-$38.9M	—	—

3. DARE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DARE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Dare Bioscience Inc. (NASDAQ: DARE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $0.68 (+0.22% 1D, market cap $13.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DARE ranks #523 in composite RQD confidence.

How does DARE compare to BFRI and RKTO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DARE carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 71.3%, and ROIC of -35.0%. By comparison, BFRI (Biofrontera Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M) and RKTO (Rocket One Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $12.8M). Among the 5-stock peer group, DARE leads on earnings multiple (N/A) while DARE leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DARE?

Per DARE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401914), Dare Bioscience Inc. generated $1.0M in revenue (+10429.4% YoY), -$13.4M in net income, and -$10.3M in free cash flow against $32.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DARE trading relative to its 50-day, 200-day, and 52-week technical levels?

DARE last traded at $0.68 (+0.22% on volume of 46,862 shares), positioning the stock -9.33% below its 50-day simple moving average ($0.75) and -56.96% below its 200-day simple moving average ($1.58). Across its 52-week range of $0.63 to $3.78, DARE sits at the 1.6% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.77).

DARE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Dare Bioscience Inc. (DARE)?

In FY 2025 (10-K), DARE converted $1.0M of revenue into a 71.3% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: DARE RQD Cockpit DARE 12M Forecast DARE Earnings & Move DARE Dividends & DRIP DARE Insiders & 13F DARE Whale Options DARE Profit Sankey DARE News & Why